Novation Companies, Inc.

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, FSNUY has a market cap of 116.9B. Regarding current trading prices, NOVC is priced at $0.01, while FSNUY trades at $12.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas FSNUY's P/E ratio is 16.42. In terms of profitability, NOVC's ROE is +0.12%, compared to FSNUY's ROE of +0.07%. Regarding short-term risk, NOVC is less volatile compared to FSNUY. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check FSNUY's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, FSNUF has a market cap of 30.6B. Regarding current trading prices, NOVC is priced at $0.01, while FSNUF trades at $54.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas FSNUF's P/E ratio is 17.25. In terms of profitability, NOVC's ROE is +0.12%, compared to FSNUF's ROE of +0.07%. Regarding short-term risk, NOVC is less volatile compared to FSNUF. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check FSNUF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, JDHIY has a market cap of 21.9B. Regarding current trading prices, NOVC is priced at $0.01, while JDHIY trades at $6.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas JDHIY's P/E ratio is 28.54. In terms of profitability, NOVC's ROE is +0.12%, compared to JDHIY's ROE of +0.09%. Regarding short-term risk, NOVC is less volatile compared to JDHIY. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check JDHIY's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, JDHIF has a market cap of 19.7B. Regarding current trading prices, NOVC is priced at $0.01, while JDHIF trades at $6.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas JDHIF's P/E ratio is 29.29. In terms of profitability, NOVC's ROE is +0.12%, compared to JDHIF's ROE of +0.09%. Regarding short-term risk, NOVC and JDHIF have similar daily volatility (0.00).Check JDHIF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, IHHHF has a market cap of 12.8B. Regarding current trading prices, NOVC is priced at $0.01, while IHHHF trades at $1.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas IHHHF's P/E ratio is 20.71. In terms of profitability, NOVC's ROE is +0.12%, compared to IHHHF's ROE of +0.07%. Regarding short-term risk, NOVC is less volatile compared to IHHHF. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check IHHHF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, FMCQF has a market cap of 12.4B. Regarding current trading prices, NOVC is priced at $0.01, while FMCQF trades at $44.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas FMCQF's P/E ratio is 15.26. In terms of profitability, NOVC's ROE is +0.12%, compared to FMCQF's ROE of +0.07%. Regarding short-term risk, NOVC and FMCQF have similar daily volatility (0.00).Check FMCQF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, BDULF has a market cap of 10.5B. Regarding current trading prices, NOVC is priced at $0.01, while BDULF trades at $0.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas BDULF's P/E ratio is 22.00. In terms of profitability, NOVC's ROE is +0.12%, compared to BDULF's ROE of +0.15%. Regarding short-term risk, NOVC and BDULF have similar daily volatility (0.00).Check BDULF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, BDUUF has a market cap of 10.3B. Regarding current trading prices, NOVC is priced at $0.01, while BDUUF trades at $0.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas BDUUF's P/E ratio is 21.67. In terms of profitability, NOVC's ROE is +0.12%, compared to BDUUF's ROE of +0.15%. Regarding short-term risk, NOVC is less volatile compared to BDUUF. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check BDUUF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, BDUUY has a market cap of 8.1B. Regarding current trading prices, NOVC is priced at $0.01, while BDUUY trades at $20.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas BDUUY's P/E ratio is 16.74. In terms of profitability, NOVC's ROE is +0.12%, compared to BDUUY's ROE of +0.15%. Regarding short-term risk, NOVC is less volatile compared to BDUUY. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check BDUUY's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, RMYHY has a market cap of 6.4B. Regarding current trading prices, NOVC is priced at $0.01, while RMYHY trades at $6.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas RMYHY's P/E ratio is 31.70. In terms of profitability, NOVC's ROE is +0.12%, compared to RMYHY's ROE of +0.06%. Regarding short-term risk, NOVC is less volatile compared to RMYHY. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check RMYHY's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, RMSYF has a market cap of 5.7B. Regarding current trading prices, NOVC is priced at $0.01, while RMSYF trades at $25.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas RMSYF's P/E ratio is 357.14. In terms of profitability, NOVC's ROE is +0.12%, compared to RMSYF's ROE of +0.06%. Regarding short-term risk, NOVC and RMSYF have similar daily volatility (0.00).Check RMSYF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, BUHPF has a market cap of 4.5B. Regarding current trading prices, NOVC is priced at $0.01, while BUHPF trades at $5.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas BUHPF's P/E ratio is 20.93. In terms of profitability, NOVC's ROE is +0.12%, compared to BUHPF's ROE of +0.26%. Regarding short-term risk, NOVC and BUHPF have similar daily volatility (0.00).Check BUHPF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, MCVEF has a market cap of 4.1B. Regarding current trading prices, NOVC is priced at $0.01, while MCVEF trades at $27.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas MCVEF's P/E ratio is 52.40. In terms of profitability, NOVC's ROE is +0.12%, compared to MCVEF's ROE of +0.16%. Regarding short-term risk, NOVC is less volatile compared to MCVEF. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check MCVEF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, ANHGY has a market cap of 4B. Regarding current trading prices, NOVC is priced at $0.01, while ANHGY trades at $5.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas ANHGY's P/E ratio is 23.87. In terms of profitability, NOVC's ROE is +0.12%, compared to ANHGY's ROE of N/A. Regarding short-term risk, NOVC and ANHGY have similar daily volatility (0.00).Check ANHGY's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, BUGDF has a market cap of 3.8B. Regarding current trading prices, NOVC is priced at $0.01, while BUGDF trades at $4.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas BUGDF's P/E ratio is 16.96. In terms of profitability, NOVC's ROE is +0.12%, compared to BUGDF's ROE of +0.26%. Regarding short-term risk, NOVC and BUGDF have similar daily volatility (0.00).Check BUGDF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, MCVEY has a market cap of 2.5B. Regarding current trading prices, NOVC is priced at $0.01, while MCVEY trades at $16.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas MCVEY's P/E ratio is 40.37. In terms of profitability, NOVC's ROE is +0.12%, compared to MCVEY's ROE of +0.14%. Regarding short-term risk, NOVC is less volatile compared to MCVEY. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check MCVEY's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, ORPEF has a market cap of 2.3B. Regarding current trading prices, NOVC is priced at $0.01, while ORPEF trades at $14.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas ORPEF's P/E ratio is 0.03. In terms of profitability, NOVC's ROE is +0.12%, compared to ORPEF's ROE of -0.13%. Regarding short-term risk, NOVC is less volatile compared to ORPEF. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check ORPEF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, EXETF has a market cap of 1.8B. Regarding current trading prices, NOVC is priced at $0.01, while EXETF trades at $18.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas EXETF's P/E ratio is 23.33. In terms of profitability, NOVC's ROE is +0.12%, compared to EXETF's ROE of +0.48%. Regarding short-term risk, NOVC is less volatile compared to EXETF. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check EXETF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, LWSCF has a market cap of 1.6B. Regarding current trading prices, NOVC is priced at $0.01, while LWSCF trades at $15.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas LWSCF's P/E ratio is 44.91. In terms of profitability, NOVC's ROE is +0.12%, compared to LWSCF's ROE of +0.07%. Regarding short-term risk, NOVC is less volatile compared to LWSCF. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check LWSCF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, RAFLF has a market cap of 1.5B. Regarding current trading prices, NOVC is priced at $0.01, while RAFLF trades at $0.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas RAFLF's P/E ratio is 26.67. In terms of profitability, NOVC's ROE is +0.12%, compared to RAFLF's ROE of +0.05%. Regarding short-term risk, NOVC is less volatile compared to RAFLF. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check RAFLF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, RHCGF has a market cap of 1.4B. Regarding current trading prices, NOVC is priced at $0.01, while RHCGF trades at $1.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas RHCGF's P/E ratio is -5.04. In terms of profitability, NOVC's ROE is +0.12%, compared to RHCGF's ROE of -0.14%. Regarding short-term risk, NOVC is less volatile compared to RHCGF. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check RHCGF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, TTALF has a market cap of 1.1B. Regarding current trading prices, NOVC is priced at $0.01, while TTALF trades at $8.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas TTALF's P/E ratio is 10.65. In terms of profitability, NOVC's ROE is +0.12%, compared to TTALF's ROE of +0.16%. Regarding short-term risk, NOVC is less volatile compared to TTALF. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check TTALF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, RKAGY has a market cap of 1.1B. Regarding current trading prices, NOVC is priced at $0.01, while RKAGY trades at $8.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas RKAGY's P/E ratio is 24.73. In terms of profitability, NOVC's ROE is +0.12%, compared to RKAGY's ROE of +0.03%. Regarding short-term risk, NOVC and RKAGY have similar daily volatility (0.00).Check RKAGY's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, RYHTY has a market cap of 1.1B. Regarding current trading prices, NOVC is priced at $0.01, while RYHTY trades at $6.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas RYHTY's P/E ratio is -4.59. In terms of profitability, NOVC's ROE is +0.12%, compared to RYHTY's ROE of -0.14%. Regarding short-term risk, NOVC and RYHTY have similar daily volatility (0.00).Check RYHTY's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, RHKJF has a market cap of 1B. Regarding current trading prices, NOVC is priced at $0.01, while RHKJF trades at $15.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas RHKJF's P/E ratio is 21.55. In terms of profitability, NOVC's ROE is +0.12%, compared to RHKJF's ROE of +0.03%. Regarding short-term risk, NOVC and RHKJF have similar daily volatility (0.00).Check RHKJF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, LTGHY has a market cap of 1B. Regarding current trading prices, NOVC is priced at $0.01, while LTGHY trades at $2.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas LTGHY's P/E ratio is -11.08. In terms of profitability, NOVC's ROE is +0.12%, compared to LTGHY's ROE of +0.38%. Regarding short-term risk, NOVC is less volatile compared to LTGHY. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check LTGHY's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, LTGHF has a market cap of 978.7M. Regarding current trading prices, NOVC is priced at $0.01, while LTGHF trades at $0.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas LTGHF's P/E ratio is -11.40. In terms of profitability, NOVC's ROE is +0.12%, compared to LTGHF's ROE of +8.48%. Regarding short-term risk, NOVC is less volatile compared to LTGHF. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check LTGHF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, NWKHY has a market cap of 854.5M. Regarding current trading prices, NOVC is priced at $0.01, while NWKHY trades at $7.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas NWKHY's P/E ratio is 10.39. In terms of profitability, NOVC's ROE is +0.12%, compared to NWKHY's ROE of +0.16%. Regarding short-term risk, NOVC and NWKHY have similar daily volatility (0.00).Check NWKHY's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, JXFGF has a market cap of 782.5M. Regarding current trading prices, NOVC is priced at $0.01, while JXFGF trades at $0.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas JXFGF's P/E ratio is -5.80. In terms of profitability, NOVC's ROE is +0.12%, compared to JXFGF's ROE of -0.11%. Regarding short-term risk, NOVC is less volatile compared to JXFGF. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check JXFGF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, WHTCF has a market cap of 696M. Regarding current trading prices, NOVC is priced at $0.01, while WHTCF trades at $2.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas WHTCF's P/E ratio is -136.22. In terms of profitability, NOVC's ROE is +0.12%, compared to WHTCF's ROE of -0.06%. Regarding short-term risk, NOVC is less volatile compared to WHTCF. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check WHTCF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, KDGTF has a market cap of 675.1M. Regarding current trading prices, NOVC is priced at $0.01, while KDGTF trades at $0.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas KDGTF's P/E ratio is -1.67. In terms of profitability, NOVC's ROE is +0.12%, compared to KDGTF's ROE of N/A. Regarding short-term risk, NOVC and KDGTF have similar daily volatility (0.00).Check KDGTF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, WFHG has a market cap of 476.9M. Regarding current trading prices, NOVC is priced at $0.01, while WFHG trades at $7.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas WFHG's P/E ratio is N/A. In terms of profitability, NOVC's ROE is +0.12%, compared to WFHG's ROE of +0.00%. Regarding short-term risk, NOVC is less volatile compared to WFHG. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check WFHG's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, ORRRY has a market cap of 371.5M. Regarding current trading prices, NOVC is priced at $0.01, while ORRRY trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas ORRRY's P/E ratio is -0.33. In terms of profitability, NOVC's ROE is +0.12%, compared to ORRRY's ROE of +7.04%. Regarding short-term risk, NOVC and ORRRY have similar daily volatility (0.00).Check ORRRY's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, BTMDW has a market cap of 292.9M. Regarding current trading prices, NOVC is priced at $0.01, while BTMDW trades at $1.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas BTMDW's P/E ratio is 0.05. In terms of profitability, NOVC's ROE is +0.12%, compared to BTMDW's ROE of -0.35%. Regarding short-term risk, NOVC is less volatile compared to BTMDW. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check BTMDW's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, MFCSF has a market cap of 219.1M. Regarding current trading prices, NOVC is priced at $0.01, while MFCSF trades at $11.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas MFCSF's P/E ratio is 15.06. In terms of profitability, NOVC's ROE is +0.12%, compared to MFCSF's ROE of +0.27%. Regarding short-term risk, NOVC and MFCSF have similar daily volatility (0.00).Check MFCSF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, MKLNF has a market cap of 214.8M. Regarding current trading prices, NOVC is priced at $0.01, while MKLNF trades at $11.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas MKLNF's P/E ratio is 19.23. In terms of profitability, NOVC's ROE is +0.12%, compared to MKLNF's ROE of +0.16%. Regarding short-term risk, NOVC and MKLNF have similar daily volatility (0.00).Check MKLNF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, CHHHF has a market cap of 165.6M. Regarding current trading prices, NOVC is priced at $0.01, while CHHHF trades at $2.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas CHHHF's P/E ratio is 8.80. In terms of profitability, NOVC's ROE is +0.12%, compared to CHHHF's ROE of +0.28%. Regarding short-term risk, NOVC and CHHHF have similar daily volatility (0.00).Check CHHHF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, HWAIF has a market cap of 160.6M. Regarding current trading prices, NOVC is priced at $0.01, while HWAIF trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas HWAIF's P/E ratio is -4.98. In terms of profitability, NOVC's ROE is +0.12%, compared to HWAIF's ROE of -0.39%. Regarding short-term risk, NOVC is less volatile compared to HWAIF. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check HWAIF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, COLRF has a market cap of 123M. Regarding current trading prices, NOVC is priced at $0.01, while COLRF trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas COLRF's P/E ratio is -8.00. In terms of profitability, NOVC's ROE is +0.12%, compared to COLRF's ROE of +0.00%. Regarding short-term risk, NOVC is less volatile compared to COLRF. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check COLRF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, VTIAF has a market cap of 111.1M. Regarding current trading prices, NOVC is priced at $0.01, while VTIAF trades at $6.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas VTIAF's P/E ratio is -9.11. In terms of profitability, NOVC's ROE is +0.12%, compared to VTIAF's ROE of -0.71%. Regarding short-term risk, NOVC is less volatile compared to VTIAF. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check VTIAF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, TOKIF has a market cap of 101.4M. Regarding current trading prices, NOVC is priced at $0.01, while TOKIF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas TOKIF's P/E ratio is -0.57. In terms of profitability, NOVC's ROE is +0.12%, compared to TOKIF's ROE of -0.83%. Regarding short-term risk, NOVC is less volatile compared to TOKIF. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check TOKIF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, NAFS has a market cap of 59.6M. Regarding current trading prices, NOVC is priced at $0.01, while NAFS trades at $0.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas NAFS's P/E ratio is N/A. In terms of profitability, NOVC's ROE is +0.12%, compared to NAFS's ROE of +0.31%. Regarding short-term risk, NOVC and NAFS have similar daily volatility (0.00).Check NAFS's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, MCIOF has a market cap of 54M. Regarding current trading prices, NOVC is priced at $0.01, while MCIOF trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas MCIOF's P/E ratio is -1.22. In terms of profitability, NOVC's ROE is +0.12%, compared to MCIOF's ROE of N/A. Regarding short-term risk, NOVC and MCIOF have similar daily volatility (0.00).Check MCIOF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, ASSF has a market cap of 45.3M. Regarding current trading prices, NOVC is priced at $0.01, while ASSF trades at $1.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas ASSF's P/E ratio is -33.33. In terms of profitability, NOVC's ROE is +0.12%, compared to ASSF's ROE of -6.63%. Regarding short-term risk, NOVC and ASSF have similar daily volatility (0.00).Check ASSF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, NVLPF has a market cap of 22.4M. Regarding current trading prices, NOVC is priced at $0.01, while NVLPF trades at $0.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas NVLPF's P/E ratio is 25.68. In terms of profitability, NOVC's ROE is +0.12%, compared to NVLPF's ROE of -0.01%. Regarding short-term risk, NOVC is less volatile compared to NVLPF. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check NVLPF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, USNU has a market cap of 22.2M. Regarding current trading prices, NOVC is priced at $0.01, while USNU trades at $1.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas USNU's P/E ratio is -9.41. In terms of profitability, NOVC's ROE is +0.12%, compared to USNU's ROE of -0.71%. Regarding short-term risk, NOVC is less volatile compared to USNU. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check USNU's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, HQDA has a market cap of 18.6M. Regarding current trading prices, NOVC is priced at $0.01, while HQDA trades at $0.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas HQDA's P/E ratio is N/A. In terms of profitability, NOVC's ROE is +0.12%, compared to HQDA's ROE of -0.06%. Regarding short-term risk, NOVC and HQDA have similar daily volatility (0.00).Check HQDA's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, GBCS has a market cap of 12.9M. Regarding current trading prices, NOVC is priced at $0.01, while GBCS trades at $4.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas GBCS's P/E ratio is -15.00. In terms of profitability, NOVC's ROE is +0.12%, compared to GBCS's ROE of +0.13%. Regarding short-term risk, NOVC is less volatile compared to GBCS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check GBCS's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, EVGRF has a market cap of 11.9M. Regarding current trading prices, NOVC is priced at $0.01, while EVGRF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas EVGRF's P/E ratio is N/A. In terms of profitability, NOVC's ROE is +0.12%, compared to EVGRF's ROE of +0.22%. Regarding short-term risk, NOVC is less volatile compared to EVGRF. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check EVGRF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, FPCG has a market cap of 10.1M. Regarding current trading prices, NOVC is priced at $0.01, while FPCG trades at $1,025.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas FPCG's P/E ratio is 0.09. In terms of profitability, NOVC's ROE is +0.12%, compared to FPCG's ROE of +0.00%. Regarding short-term risk, NOVC and FPCG have similar daily volatility (0.00).Check FPCG's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, HLYK has a market cap of 8.1M. Regarding current trading prices, NOVC is priced at $0.01, while HLYK trades at $3.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas HLYK's P/E ratio is -2.39. In terms of profitability, NOVC's ROE is +0.12%, compared to HLYK's ROE of +0.88%. Regarding short-term risk, NOVC is less volatile compared to HLYK. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check HLYK's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, BICX has a market cap of 7.6M. Regarding current trading prices, NOVC is priced at $0.01, while BICX trades at $0.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas BICX's P/E ratio is -1.25. In terms of profitability, NOVC's ROE is +0.12%, compared to BICX's ROE of +0.41%. Regarding short-term risk, NOVC and BICX have similar daily volatility (0.00).Check BICX's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, RVLWF has a market cap of 5.4M. Regarding current trading prices, NOVC is priced at $0.01, while RVLWF trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas RVLWF's P/E ratio is -0.30. In terms of profitability, NOVC's ROE is +0.12%, compared to RVLWF's ROE of +3.95%. Regarding short-term risk, NOVC and RVLWF have similar daily volatility (0.00).Check RVLWF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, NUMIF has a market cap of 4M. Regarding current trading prices, NOVC is priced at $0.01, while NUMIF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas NUMIF's P/E ratio is -0.41. In terms of profitability, NOVC's ROE is +0.12%, compared to NUMIF's ROE of +11.51%. Regarding short-term risk, NOVC is less volatile compared to NUMIF. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check NUMIF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, VLXC has a market cap of 3.9M. Regarding current trading prices, NOVC is priced at $0.01, while VLXC trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas VLXC's P/E ratio is -4.00. In terms of profitability, NOVC's ROE is +0.12%, compared to VLXC's ROE of +0.74%. Regarding short-term risk, NOVC is less volatile compared to VLXC. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check VLXC's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, XCRT has a market cap of 3.6M. Regarding current trading prices, NOVC is priced at $0.01, while XCRT trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas XCRT's P/E ratio is N/A. In terms of profitability, NOVC's ROE is +0.12%, compared to XCRT's ROE of +0.26%. Regarding short-term risk, NOVC is less volatile compared to XCRT. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check XCRT's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, RHEP has a market cap of 2.9M. Regarding current trading prices, NOVC is priced at $0.01, while RHEP trades at $1.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas RHEP's P/E ratio is -7.53. In terms of profitability, NOVC's ROE is +0.12%, compared to RHEP's ROE of -0.04%. Regarding short-term risk, NOVC is less volatile compared to RHEP. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check RHEP's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, EPWCF has a market cap of 2.5M. Regarding current trading prices, NOVC is priced at $0.01, while EPWCF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas EPWCF's P/E ratio is -0.00. In terms of profitability, NOVC's ROE is +0.12%, compared to EPWCF's ROE of +0.00%. Regarding short-term risk, NOVC is less volatile compared to EPWCF. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check EPWCF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, NRPR has a market cap of 2.1M. Regarding current trading prices, NOVC is priced at $0.01, while NRPR trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas NRPR's P/E ratio is -0.03. In terms of profitability, NOVC's ROE is +0.12%, compared to NRPR's ROE of N/A. Regarding short-term risk, NOVC and NRPR have similar daily volatility (0.00).Check NRPR's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, GRST has a market cap of 1.5M. Regarding current trading prices, NOVC is priced at $0.01, while GRST trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas GRST's P/E ratio is N/A. In terms of profitability, NOVC's ROE is +0.12%, compared to GRST's ROE of +0.17%. Regarding short-term risk, NOVC and GRST have similar daily volatility (0.00).Check GRST's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, KJFI has a market cap of 1.5M. Regarding current trading prices, NOVC is priced at $0.01, while KJFI trades at $0.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas KJFI's P/E ratio is -0.06. In terms of profitability, NOVC's ROE is +0.12%, compared to KJFI's ROE of +0.00%. Regarding short-term risk, NOVC is less volatile compared to KJFI. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check KJFI's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, SMAS has a market cap of 1.5M. Regarding current trading prices, NOVC is priced at $0.01, while SMAS trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas SMAS's P/E ratio is N/A. In terms of profitability, NOVC's ROE is +0.12%, compared to SMAS's ROE of N/A. Regarding short-term risk, NOVC is less volatile compared to SMAS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check SMAS's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, MDGP has a market cap of 1.5M. Regarding current trading prices, NOVC is priced at $0.01, while MDGP trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas MDGP's P/E ratio is N/A. In terms of profitability, NOVC's ROE is +0.12%, compared to MDGP's ROE of -2.19%. Regarding short-term risk, NOVC and MDGP have similar daily volatility (0.00).Check MDGP's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, MAHN has a market cap of 1.3M. Regarding current trading prices, NOVC is priced at $0.01, while MAHN trades at $0.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas MAHN's P/E ratio is 55.00. In terms of profitability, NOVC's ROE is +0.12%, compared to MAHN's ROE of N/A. Regarding short-term risk, NOVC is less volatile compared to MAHN. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check MAHN's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, JRSS has a market cap of 1.1M. Regarding current trading prices, NOVC is priced at $0.01, while JRSS trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas JRSS's P/E ratio is -0.13. In terms of profitability, NOVC's ROE is +0.12%, compared to JRSS's ROE of -0.09%. Regarding short-term risk, NOVC is less volatile compared to JRSS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check JRSS's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, DPAT has a market cap of 1.1M. Regarding current trading prices, NOVC is priced at $0.01, while DPAT trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas DPAT's P/E ratio is -2.25. In terms of profitability, NOVC's ROE is +0.12%, compared to DPAT's ROE of +0.45%. Regarding short-term risk, NOVC and DPAT have similar daily volatility (0.00).Check DPAT's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, PHMB has a market cap of 1.1M. Regarding current trading prices, NOVC is priced at $0.01, while PHMB trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas PHMB's P/E ratio is N/A. In terms of profitability, NOVC's ROE is +0.12%, compared to PHMB's ROE of N/A. Regarding short-term risk, NOVC is less volatile compared to PHMB. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check PHMB's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, GNOW has a market cap of 859.7K. Regarding current trading prices, NOVC is priced at $0.01, while GNOW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas GNOW's P/E ratio is -0.01. In terms of profitability, NOVC's ROE is +0.12%, compared to GNOW's ROE of -12.49%. Regarding short-term risk, NOVC and GNOW have similar daily volatility (0.00).Check GNOW's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, MSITF has a market cap of 480K. Regarding current trading prices, NOVC is priced at $0.01, while MSITF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas MSITF's P/E ratio is -0.10. In terms of profitability, NOVC's ROE is +0.12%, compared to MSITF's ROE of N/A. Regarding short-term risk, NOVC is less volatile compared to MSITF. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check MSITF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, ARPC has a market cap of 336.6K. Regarding current trading prices, NOVC is priced at $0.01, while ARPC trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas ARPC's P/E ratio is N/A. In terms of profitability, NOVC's ROE is +0.12%, compared to ARPC's ROE of +3.10%. Regarding short-term risk, NOVC is less volatile compared to ARPC. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check ARPC's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, NXGT has a market cap of 292.2K. Regarding current trading prices, NOVC is priced at $0.01, while NXGT trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas NXGT's P/E ratio is N/A. In terms of profitability, NOVC's ROE is +0.12%, compared to NXGT's ROE of +0.04%. Regarding short-term risk, NOVC and NXGT have similar daily volatility (0.00).Check NXGT's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, BNYN has a market cap of 286K. Regarding current trading prices, NOVC is priced at $0.01, while BNYN trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas BNYN's P/E ratio is N/A. In terms of profitability, NOVC's ROE is +0.12%, compared to BNYN's ROE of -14.10%. Regarding short-term risk, NOVC is less volatile compared to BNYN. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check BNYN's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, SETO has a market cap of 234.5K. Regarding current trading prices, NOVC is priced at $0.01, while SETO trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas SETO's P/E ratio is -1.88. In terms of profitability, NOVC's ROE is +0.12%, compared to SETO's ROE of -123.80%. Regarding short-term risk, NOVC is less volatile compared to SETO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check SETO's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, FCHS has a market cap of 131.8K. Regarding current trading prices, NOVC is priced at $0.01, while FCHS trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas FCHS's P/E ratio is -0.04. In terms of profitability, NOVC's ROE is +0.12%, compared to FCHS's ROE of +0.20%. Regarding short-term risk, NOVC and FCHS have similar daily volatility (0.00).Check FCHS's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, TPIA has a market cap of 113.8K. Regarding current trading prices, NOVC is priced at $0.01, while TPIA trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas TPIA's P/E ratio is -0.15. In terms of profitability, NOVC's ROE is +0.12%, compared to TPIA's ROE of +0.55%. Regarding short-term risk, NOVC is less volatile compared to TPIA. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check TPIA's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, AMBD has a market cap of 85.6K. Regarding current trading prices, NOVC is priced at $0.01, while AMBD trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas AMBD's P/E ratio is N/A. In terms of profitability, NOVC's ROE is +0.12%, compared to AMBD's ROE of +1.11%. Regarding short-term risk, NOVC is less volatile compared to AMBD. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check AMBD's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, JNHMF has a market cap of 69.7K. Regarding current trading prices, NOVC is priced at $0.01, while JNHMF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas JNHMF's P/E ratio is -0.01. In terms of profitability, NOVC's ROE is +0.12%, compared to JNHMF's ROE of -3.60%. Regarding short-term risk, NOVC is less volatile compared to JNHMF. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check JNHMF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, NMHLY has a market cap of 41.7K. Regarding current trading prices, NOVC is priced at $0.01, while NMHLY trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas NMHLY's P/E ratio is 0.02. In terms of profitability, NOVC's ROE is +0.12%, compared to NMHLY's ROE of N/A. Regarding short-term risk, NOVC and NMHLY have similar daily volatility (0.00).Check NMHLY's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, CLRD has a market cap of 28.8K. Regarding current trading prices, NOVC is priced at $0.01, while CLRD trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas CLRD's P/E ratio is -0.01. In terms of profitability, NOVC's ROE is +0.12%, compared to CLRD's ROE of +0.38%. Regarding short-term risk, NOVC is less volatile compared to CLRD. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check CLRD's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, MSGP has a market cap of 26K. Regarding current trading prices, NOVC is priced at $0.01, while MSGP trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas MSGP's P/E ratio is N/A. In terms of profitability, NOVC's ROE is +0.12%, compared to MSGP's ROE of +0.27%. Regarding short-term risk, NOVC is less volatile compared to MSGP. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check MSGP's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, DRWN has a market cap of 24K. Regarding current trading prices, NOVC is priced at $0.01, while DRWN trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas DRWN's P/E ratio is N/A. In terms of profitability, NOVC's ROE is +0.12%, compared to DRWN's ROE of -0.01%. Regarding short-term risk, NOVC and DRWN have similar daily volatility (0.00).Check DRWN's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, HSMD has a market cap of 18.4K. Regarding current trading prices, NOVC is priced at $0.01, while HSMD trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas HSMD's P/E ratio is -0.01. In terms of profitability, NOVC's ROE is +0.12%, compared to HSMD's ROE of -0.04%. Regarding short-term risk, NOVC and HSMD have similar daily volatility (0.00).Check HSMD's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, SCAL has a market cap of 17.4K. Regarding current trading prices, NOVC is priced at $0.01, while SCAL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas SCAL's P/E ratio is 0.04. In terms of profitability, NOVC's ROE is +0.12%, compared to SCAL's ROE of +0.07%. Regarding short-term risk, NOVC and SCAL have similar daily volatility (0.00).Check SCAL's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, CEVE has a market cap of 17.1K. Regarding current trading prices, NOVC is priced at $0.01, while CEVE trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas CEVE's P/E ratio is N/A. In terms of profitability, NOVC's ROE is +0.12%, compared to CEVE's ROE of +2.26%. Regarding short-term risk, NOVC and CEVE have similar daily volatility (0.00).Check CEVE's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, PRMD has a market cap of 12.9K. Regarding current trading prices, NOVC is priced at $0.01, while PRMD trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas PRMD's P/E ratio is N/A. In terms of profitability, NOVC's ROE is +0.12%, compared to PRMD's ROE of +0.73%. Regarding short-term risk, NOVC is less volatile compared to PRMD. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check PRMD's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, GENN has a market cap of 12.1K. Regarding current trading prices, NOVC is priced at $0.01, while GENN trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas GENN's P/E ratio is -0.01. In terms of profitability, NOVC's ROE is +0.12%, compared to GENN's ROE of +0.07%. Regarding short-term risk, NOVC is less volatile compared to GENN. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check GENN's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, CHCR has a market cap of 12K. Regarding current trading prices, NOVC is priced at $0.01, while CHCR trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas CHCR's P/E ratio is -0.00. In terms of profitability, NOVC's ROE is +0.12%, compared to CHCR's ROE of N/A. Regarding short-term risk, NOVC and CHCR have similar daily volatility (0.00).Check CHCR's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, ACGI has a market cap of 10.5K. Regarding current trading prices, NOVC is priced at $0.01, while ACGI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas ACGI's P/E ratio is N/A. In terms of profitability, NOVC's ROE is +0.12%, compared to ACGI's ROE of +1.11%. Regarding short-term risk, NOVC is less volatile compared to ACGI. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check ACGI's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, WEQL has a market cap of 7.2K. Regarding current trading prices, NOVC is priced at $0.01, while WEQL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas WEQL's P/E ratio is N/A. In terms of profitability, NOVC's ROE is +0.12%, compared to WEQL's ROE of +0.21%. Regarding short-term risk, NOVC is less volatile compared to WEQL. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check WEQL's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, PAOG has a market cap of 5K. Regarding current trading prices, NOVC is priced at $0.01, while PAOG trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas PAOG's P/E ratio is N/A. In terms of profitability, NOVC's ROE is +0.12%, compared to PAOG's ROE of +0.03%. Regarding short-term risk, NOVC is less volatile compared to PAOG. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check PAOG's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, SLHGF has a market cap of 4K. Regarding current trading prices, NOVC is priced at $0.01, while SLHGF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas SLHGF's P/E ratio is N/A. In terms of profitability, NOVC's ROE is +0.12%, compared to SLHGF's ROE of -0.42%. Regarding short-term risk, NOVC is less volatile compared to SLHGF. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check SLHGF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, SLHPF has a market cap of 3.9K. Regarding current trading prices, NOVC is priced at $0.01, while SLHPF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas SLHPF's P/E ratio is N/A. In terms of profitability, NOVC's ROE is +0.12%, compared to SLHPF's ROE of -0.42%. Regarding short-term risk, NOVC is less volatile compared to SLHPF. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check SLHPF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, ERUC has a market cap of 3.9K. Regarding current trading prices, NOVC is priced at $0.01, while ERUC trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas ERUC's P/E ratio is N/A. In terms of profitability, NOVC's ROE is +0.12%, compared to ERUC's ROE of N/A. Regarding short-term risk, NOVC and ERUC have similar daily volatility (0.00).Check ERUC's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, BBAL has a market cap of 3.4K. Regarding current trading prices, NOVC is priced at $0.01, while BBAL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas BBAL's P/E ratio is N/A. In terms of profitability, NOVC's ROE is +0.12%, compared to BBAL's ROE of +0.45%. Regarding short-term risk, NOVC and BBAL have similar daily volatility (0.00).Check BBAL's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, NMMCF has a market cap of 2.1K. Regarding current trading prices, NOVC is priced at $0.01, while NMMCF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas NMMCF's P/E ratio is N/A. In terms of profitability, NOVC's ROE is +0.12%, compared to NMMCF's ROE of +0.21%. Regarding short-term risk, NOVC is less volatile compared to NMMCF. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check NMMCF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, PPRG has a market cap of 1.6K. Regarding current trading prices, NOVC is priced at $0.01, while PPRG trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas PPRG's P/E ratio is N/A. In terms of profitability, NOVC's ROE is +0.12%, compared to PPRG's ROE of -0.58%. Regarding short-term risk, NOVC and PPRG have similar daily volatility (0.00).Check PPRG's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, KONEF has a market cap of 1.6K. Regarding current trading prices, NOVC is priced at $0.01, while KONEF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas KONEF's P/E ratio is N/A. In terms of profitability, NOVC's ROE is +0.12%, compared to KONEF's ROE of -6.56%. Regarding short-term risk, NOVC is less volatile compared to KONEF. This indicates potentially lower risk in terms of short-term price fluctuations for NOVC.Check KONEF's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, OHAQ has a market cap of 1.4K. Regarding current trading prices, NOVC is priced at $0.01, while OHAQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas OHAQ's P/E ratio is 0.01. In terms of profitability, NOVC's ROE is +0.12%, compared to OHAQ's ROE of +0.09%. Regarding short-term risk, NOVC and OHAQ have similar daily volatility (0.00).Check OHAQ's competition here

NOVC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVC stands at 1.2M. In comparison, BNKL has a market cap of 1.2K. Regarding current trading prices, NOVC is priced at $0.01, while BNKL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVC currently has a P/E ratio of -0.20, whereas BNKL's P/E ratio is N/A. In terms of profitability, NOVC's ROE is +0.12%, compared to BNKL's ROE of -7.69%. Regarding short-term risk, NOVC and BNKL have similar daily volatility (0.00).Check BNKL's competition here